From "Special K" to "Special M": The Evolution of the Recreational Use of Ketamine and Methoxetamine

被引:93
作者
Corazza, Ornella [1 ]
Assi, Sulaf [1 ]
Schifano, Fabrizio [1 ]
机构
[1] Univ Hertfordshire, Sch Life & Med Sci, Hatfield AL10 9AB, Herts, England
关键词
Ketamine; Methoxetamine; Near-death experience; Phencyclidine; Psychoactive; NEAR-DEATH EXPERIENCE; NMDA; PAIN; PHARMACOKINETICS; SCHIZOPHRENIA; INFUSION; HOLE;
D O I
10.1111/cns.12063
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This article reviews the recreational use of ketamine (Special K; KET) and explores the recent diffusion of its new derivative methoxetamine (Special M; MXE). The literature search on the nonclinical/recreational use of KET and MXE was carried out in a range of medical databases. Considering the limitations of peer-reviewed information, data were integrated with a qualitative assessment of a range of websites, drug fora, and other online resources including e-newsgroups, chat rooms, mailing lists, e-newsletters, and bulletin boards. The recreational use of KET has started since its discovery in 1962. This was due to its rapid onset, short duration of action, and peculiar psychotropic effects (K-hole). The latter effect ranges from confusion to dissociation and depersonalization (near-death experience). However, KET abuse is often associated with physical and psychological side effects, of which the worst is urological/bladder toxicity. Recently, MXE has emerged as a legal and bladder-friendly KET alternative. MXE presents with the same dissociative effect of KET, but with slower onset and longer duration of action. However, MXE seems to be associated with worse side effects than KET, ranging from mood disturbances/suicidal attempts to acute cerebellar toxicity. After 50years of its discovery, KET has led to the emergence of MXE. However, this latter derivative does not appear to be a safer alternative to KET itself.
引用
收藏
页码:454 / 460
页数:7
相关论文
共 53 条
  • [41] Ketamine
    Quibell, Rachel
    Prommer, Eric E.
    Mihalyo, Mary
    Twycross, Robert
    Wilcock, Andrew
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2011, 41 (03) : 640 - 649
  • [42] Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo
    Robson, Matthew J.
    Elliott, Meenal
    Seminerio, Michael J.
    Matsumoto, Rae R.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 (04) : 308 - 317
  • [43] Rowland LM, 2005, AVIAT SPACE ENVIR MD, V76, pC52
  • [44] Trapped in the "K-hole" - Overview of deaths associated with ketamine misuse in the UK (1993-2006)
    Schifano, Fabrizio
    Corkery, John
    Oyefeso, Adenekan
    Tonia, Thomy
    Ghodse, Abdol Harnid
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (01) : 114 - 116
  • [45] Sehdev Rajesh S, 2006, Emerg Med Australas, V18, P37
  • [46] Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation
    Shields, Jennifer E.
    Dargan, Paul I.
    Wood, David M.
    Puchnarewicz, Malgorzata
    Davies, Susannah
    Waring, W. Stephen
    [J]. CLINICAL TOXICOLOGY, 2012, 50 (05) : 438 - 440
  • [47] SIEGEL R K, 1978, National Institute on Drug Abuse Research Monograph, P119
  • [48] Stevenson C, 2003, KETAMINE REV
  • [49] The Independent, 2009, KET TOPS COC NEW DRU
  • [50] Near-death experience in survivors of cardiac arrest: a prospective study in the Netherlands
    van Lommel, P
    van Wees, R
    Meyers, V
    Elfferich, I
    [J]. LANCET, 2001, 358 (9298) : 2039 - 2045